In the vast field of life science research, the stability and integrity of RNA (ribonucleic acid) is crucial to the success of many experiments. RNA, as a messenger of genetic information, plays a core role in various biological processes within cells. However, the fragility of RNA, especially its high sensitivity to ribonucleases (RNases), has been a significant challenge for researchers. RNases are a class of enzymes widely present that can catalyze the degradation of RNA into small RNA molecules, and even minute RNase contamination can lead to complete degradation of RNA samples. This degradation not only affects the accuracy of experimental results but could even lead to the failure of entire studies. Therefore, preventing RNase contamination and protecting the integrity of RNA has become a key consideration in the design of many experiments.

In the complex and ever-changing field of cancer, scientists are constantly exploring new treatment strategies and targets. In recent years, NFAT (Nuclear Factor of Activated T-cells) has garnered significant attention as a potential target for cancer treatment. Particularly, inhibitors targeting NFAT, such as the VIVIT peptide, have become focal points in cancer research. As a global leader in high-performance life science products, Glpbio's exploration and innovation in this field have unveiled the immense potential of NFAT inhibitors in cancer therapy.